Evidence map›Paper›PMID 40548383›Full record

ArticleEpidemiology and infection2025

Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023.

Brenda L Coleman, Nicole M Robertson, Robyn A Harrison, Louis Valiquette, Joanne M Langley, Matthew P Muller, Curtis L Cooper, Jeya Nadarajah, Jeff Powis, Saranya Arnoldo and 6 more

Abstract read
In one paragraph

Article in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brenda L Colemanhttps://ror.org/03dbr7087University of Toronto, School of Public Health, Toronto, ON, Canada.
Nicole M RobertsonSinai Health, Toronto, ON, Canada.
Robyn A HarrisonDivision of Infectious Diseases, https://ror.org/0160cpw27University of Alberta, AB, Canada.
Louis ValiquetteDept of Microbiology & Infectious Diseases, https://ror.org/020r51985Centre Hospitalier Universitaire de Sherbrooke, QC, Canada.
Joanne M LangleyCanadian Center for Vaccinology, Dalhousie University, IWK Health and Nova Scotia Health, HalifaxNS, Canada.
Matthew P Mullerhttps://ror.org/03dbr7087University of Toronto, School of Public Health, Toronto, ON, Canada.
Curtis L CooperFaculty of Medicine, https://ror.org/03c4mmv16University of Ottawa, OttawaON, Canada.
Jeya Nadarajahhttps://ror.org/01safxj67Oak Valley Health, Markham, ON, Canada.
Jeff PowisMichael Garron Hospital, Toronto, ON, Canada.
Saranya Arnoldohttps://ror.org/03dbr7087University of Toronto, School of Public Health, Toronto, ON, Canada.
Marek Smiejahttps://ror.org/012x5xb44Unity Health Toronto, Toronto, ON, Canada.
Otto G Vanderkooihttps://ror.org/00sx29x36Alberta Children's Hospital, Calgary, AB, Canada.
Freda QiSinai Health, Toronto, ON, Canada.
Karen ColwillSinai Health, Toronto, ON, Canada.
Anne Claude GingrasSinai Health, Toronto, ON, Canada.
Allison McGeerhttps://ror.org/03dbr7087University of Toronto, School of Public Health, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining the factors that impact the risk for infection with SARS-CoV-2 is a priority as the virus continues to infect people worldwide. The objective was to determine the effectiveness of vaccines and other factors associated with infection among Canadian healthcare workers (HCWs) followed from 15 June 2020 to 1 December 2023. We also investigate the association between antibodies to SARS-CoV-2 and subsequent infections with SARS-CoV-2. Of the 2474 eligible participants, 2133 (86%) were female, 33% were nurses, the median age was 41 years, and 99.3% had received at least two doses of COVID-19 vaccine by 31 December 2021. The incidence of SARS-CoV-2 was 0.91 per 1000 person-days. Prior to the circulation of the Omicron variants, vaccine effectiveness (VE) was estimated at 85% (95% CI 1, 98) for participants who received the primary series of vaccine. During the Omicron period, relative adjusted VE was 43% (95% CI 29, 54), 56% (95% CI 42, 67), and 46% (95% CI 24, 62) for 3, 4, and ≥ 5 doses compared with those who received primary series after adjusting for previous infection and other covariates. Exposure to infected household members, coworkers, or friends in the previous 14 days were risk factor for infection, while contact with an infected patient was not statistically significant. Participants with higher levels of immunoglobulin G (IgG) anti-receptor binding domain (RBD) antibodies had lower rates of infection than those with the lowest levels. COVID-19 vaccines remained effective throughout the follow-up of this cohort of highly vaccinated HCWs. IgG anti-RBD antibody levels may be useful as correlates of protection for issues such as vaccine development and testing. There remains a need to increase the awareness among HCWs about the risk of contracting SARS-CoV-2 from contacts at a variety of venues.

Indexed as

COVID-19COVID-19 VaccinesHealth PersonnelSARS-CoV-2AdultAntibodies, ViralCanadaCohort StudiesFemaleHumansIncidenceMaleMiddle AgedRisk FactorsVaccine EfficacyYoung AdultAntibodies, ViralCOVID-19 Vaccinesantibody levelhealthcare workersrisk factorsSARS-CoV-2vaccine effectiveness

Identifiers

PMID40548383
PMCPMC12188280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.